{"schema_version":"secwatch.filing_event.v1","accession":"0000805928-24-000107","form_type":"8-K","ticker":"AXGN","cik":"0000805928","company_name":"Axogen, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.935019+00:00","generated_at":"2026-05-31T11:26:18.892424+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Axogen Q2 revenue up 25.6% to $47.9M; net loss narrows; raises FY guidance","bullets":["Revenue $47.9M (+25.6% YoY); net loss $1.9M ($0.04/share) vs $6.7M loss prior year.","Adjusted net income $2.0M ($0.05/share); adjusted EBITDA $5.6M vs loss $0.2M.","FY2024 revenue guidance raised to $182-186M; gross margin guidance adjusted to 74-76%.","Rolling BLA submission for Avance Nerve Graft initiated; expects completion Q3 2024, potential approval mid-2025.","Launched Avive+ Soft Tissue Matrix in June; Core accounts up 18.7% to 412."],"urls":{"canonical":"https://secwatch.observer/filing/0000805928-24-000107","json":"https://secwatch.observer/filing/0000805928-24-000107.json","markdown":"https://secwatch.observer/filing/0000805928-24-000107.md","text":"https://secwatch.observer/filing/0000805928-24-000107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000107/0000805928-24-000107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/805928/000080592824000107/axgn-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:26:18.892424+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}